QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Patients with metastatic castration-resistant prostate cancer (mCRPC) usually have limited response to immunotherapy. However, a Phase II trial found that an immunotherapy drug benefitted certain patients with this type of prostate cancer. The patients had a specific type of immune…
The 2020 American Urological Association (AUA) conference was held virtually June 27-28, 2020. Dr. Catalona shared his expertise and opinions as a featured speaker and was honored with the association’s most prestigious award. Dr. Catalona Argues that Biopsies are Still…
by Betsy Haberl In 2015, Chicago artist Chris Newman was diagnosed with prostate cancer. This summer, he is five years out from his surgery with Dr. Catalona and celebrating seeing one of his sculptures on display in downtown Chicago. For…
by William J. Catalona, M.D. Many hospitals and surgeons are committed to robotic surgery technology. In this regard, it has been claimed that 85% of the thousands of radical prostatectomies performed each year are now performed robotically. However, the FDA…
Earlier this year, the national media reported on two studies that examined the impact of lengthening PSA screening intervals based on a patient’s PSA value. The studies sought to determine if patients who had low PSA values when they are…
Family History of Breast Cancer is a Risk Factor for Prostate Cancer An analysis of 18 studies involving more than 17 million people found that a history of breast cancer in first-degree relatives was associated with an 18% increased risk…
In May, the U.S. Food and Drug Administration (FDA) approved two PARP inhibitors for men with certain genetic mutations and metastatic castration-resistant prostate cancer (mCRPC). The two drugs are olaparib (brand name Lynparza) and rucaparib (brand name Rubraca). Both of…
Research exploring the cause for increased risks of cardiovascular problems in prostate cancer patients on ADT hypothesizes the effect could be related to a link between testosterone levels and heart rhythm issues. Androgen-deprivation therapy (ADT) suppresses levels of androgens, including…
Every year, the American Cancer Society releases new estimates on cancer cases and deaths in the U.S. The report in the journal CA: A Cancer Journal for Clinicians contained some excellent news: the cancer death rate has fallen continuously from…
The URF’s thoughts are with those affected by the coronavirus (COVID-19) pandemic. The Prostate Cancer Foundation has published special precautions for prostate cancer patients and their friends and loved ones during the coronavirus (COVID-19) pandemic. The coronavirus can affect the…
"*" indicates required fields
